XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
  Depression
  Neuropsychiatry
  Personality Disorders
  Bulimia
  Anxiety
  Substance Abuse
   Alcohol
   Smoking
   Amphetamine
   Opiates
   Cannabis
   Cocaine
  Suicide
  CFS
  Psychoses
  Child Psychiatry
  Learning-Disabilities
  Psychology
  Forensic Psychiatry
  Mood Disorders
  Sleep Disorders
  Peri-Natal Psychiatry
  Psychotherapy
  Anorexia Nervosa
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Smoking Channel
subscribe to Smoking newsletter

Latest Research : Psychiatry : Substance Abuse : Smoking

   DISCUSS   |   EMAIL   |   PRINT
Reviewing evidence for effectiveness of gene-based smoking cessation
Jan 23, 2006 - 5:20:00 PM, Reviewed by: Dr. Ankush Vidyarthi

There is also preliminary evidence to support a relationship between eating disorders and smoking, with smoking being used to control weight.

 
n editorial in the January 2006 issue of the Psychiatric Bulletin reviews the evidence for the effectiveness of gene-based smoking cessation packages, and asks whether they are appropriate for psychiatric patients.

It is well known that the prevalence of smoking among psychiatric patients is far higher than in the general public (70% v. 30%). Smoking in schizophrenia and depression is thought in part to be an attempt to self-medicate symptoms of the illness.

There is also preliminary evidence to support a relationship between eating disorders and smoking, with smoking being used to control weight.

As clinicians working with patients with such high smoking rates, psychiatrists have a duty of care to protect them from the harmful effects of tobacco smoke. This involves informing patients of the best treatment available, and directing them to the appropriate services.

The mainstays of current smoking cessation treatment are nicotine replacement therapy (patches, gum, inhalers, lozenges and spray) and bupropion (Zyban), although behavioural support is also effective.

Gene-based tests for smoking cessation are currently marketed privately to smokers via the internet to help inform them whether they carry gene variants predisposing them to nicotine addiction. The results are given with a personally tailored plan to stop smoking, including medication, behavioural changes and alternative therapies.

Should psychiatric patients be advised to purchase gene-based tests? There are several issues to be considered:

* Genetic association studies are inconclusive with regard to the best genetic candidates in the smoking cessation field
* The responsibilities of general adult psychiatrists, substance misuse service professionals and general practitioners are already significant, without the additional burden of informing themselves about, and providing counselling on, gene-based therapies
* The cost implications for the NHS of this added duty is of concern
* Current privacy laws within the UK fail to protect patients from the misuse of genetic information. Many European countries have laws preventing insurers and prospective employers from gaining access to an individual's genetic profile. When patients spend money on a genetic test for smoking cessation, they are inadvertently generating information about their risk of predisposition to developing or possessing a number of other stigmatising conditions, such as alcohol or cocaine addiction, or pathological gambling
* The majority of people who attempt to give up smoking using genetic tests will fail -success rates are as low as 20% in a year
* Information provided to patients from the test may mislead them into thinking they have a particularly virulent or 'genetic' form of addiction, and are never going to be able to give up.

The authors of the editorial conclude that more research is needed to verify the usefulness of genetic tests for smoking cessation, especially among general medical and psychiatric patients.

Until there is greater understanding of the genetic influences in nicotine addiction, patients being cared for in psychiatric services are best advised to avoid such tests.
 

- O'Gara C and Munafo M (2006) Psychiatric patients and gene-based smoking cessation packages. Psychiatric Bulletin, 30, 1-2.
 

pb.rcpsych.org

 
Subscribe to Smoking Newsletter
E-mail Address:

 



Related Smoking News

C. elegans provides model for the genetics of nicotine dependence
Smoking Ban Associated With Rapid Improvement In Health Of Bar Workers in Scotland
Smoking media literacy (SML) is a valuable tool in efforts to discourage teens from smoking
Hold the Hookah
Weight concerns affects women's motivations to stay smoke-free after delivery
Nicotine Withdrawal Begins Within 30 Minutes
Varenicline Appears Effective In Helping Smokers Kick The Habit
Smokers with chronic pain smoke more
Varenicline Prevents Relapse of Smoking Behaviour
Varenicline produce higher continuous smoking abstinence rates


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us